The FDA, which has been crafting rules for CBD products since 2019, says it is seeking partnerships, from academia to government and the cannabis industry, to “develop the foundation for more robust CBD data collection.”
The Food and Drug Law Institute is hosting officials from several federal agencies this week to discuss cannabis policies.
One company is focused on the future of CBD in supplements. The other, on its future in pharmaceuticals.
During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.
Among the new names on the list of entities seeking to discuss the FDA’s forthcoming rules on CBD products: American Bankers Association and Columbia Care.
Epidiolex contains cannabidiol, or CBD, extracted from cannabis plants, and was first approved to treat severe forms of epilepsy.
The Food and Drug Administration drafted its long-awaited CBD policy, and sent it to the White House Office of Management and Budget for approval, a final step before publication.
The US Department of Transportation committee heard a presentation and asked questions about how the passage of the 2018 Farm Bill, and proliferation of CBD, is affecting the nation’s commercial drivers.
Consumer Brands Association, which counts among its members Kellogg’s, Coca-Cola Company, and PepsiCo, Inc., brought together a diverse group to focus on federal CBD policies.
Figi’s story raised awareness about the potential for CBD to reduce seizures, and led to CBD legislation and research around the world.
The DEA has taken Epidiolex, a CBD-based formula for rare forms of epilepsy, completely off its list of controlled substances. Why? The 2018 Farm Bill.
The Agency is specifically looking to collect “scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.”
The FDA is reopening public comment, collaborating with global regulators on how to handle cannabinoids, and backing research on CBD and “dermal penetration.”
At NASDA Winter Policy Conference, USDA says it’s loosening DEA lab testing requirement for hemp, and FDA signals openness to non-pharma CBD products.
Consumer Brands Association—think Kellogg's, Pepsi, etc.—has created a high-voltage advisory board to frame its advocacy approach.
The CBD industry has long awaited the FDA’s regulatory approach to CBD products, which the agency says it will unveil “in the coming weeks.”